Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Optinose Inc (OPTN)

Optinose Inc (OPTN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 323,510
  • Shares Outstanding, K 41,264
  • Annual Sales, $ 7,070 K
  • Annual Income, $ -106,660 K
  • 60-Month Beta 1.09
  • Price/Sales 46.02
  • Price/Cash Flow N/A
  • Price/Book 3.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.72
  • Number of Estimates 2
  • High Estimate -0.69
  • Low Estimate -0.75
  • Prior Year -0.64
  • Growth Rate Est. (year over year) -12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.94 +31.99%
on 06/07/19
8.96 -12.50%
on 05/22/19
-0.86 (-9.89%)
since 05/21/19
3-Month
5.94 +31.99%
on 06/07/19
11.23 -30.19%
on 04/02/19
-1.63 (-17.21%)
since 03/21/19
52-Week
5.66 +38.52%
on 12/21/18
30.00 -73.87%
on 07/09/18
-17.17 (-68.65%)
since 06/21/18

Most Recent Stories

More News
Optinose to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present...

OPTN : 7.84 (-0.51%)
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates

OptiNose (OPTN) delivered earnings and revenue surprises of 1.41% and 2.99%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

OPTN : 7.84 (-0.51%)
OptiNose: 1Q Earnings Snapshot

YARDLEY, Pa. (AP) _ OptiNose Inc. (OPTN) on Thursday reported a loss of $28.9 million in its first quarter.

OPTN : 7.84 (-0.51%)
Optinose Reports First Quarter 2019 Financial Results and Recent Operational Highlights

Company reports first quarter 2019 total revenues of $4.5 million.

OPTN : 7.84 (-0.51%)
MERGER INVESTIGATION NOTICE: Kaskela Law LLC Announces Shareholder Investigation of BioScrip, Inc. - BIOS

Kaskela Law LLC announces that it is investigating BioScrip, Inc. ("BioScrip" or the "Company") (Nasdaq: BIOS) on behalf of the Company's shareholders.

BIOS : 2.31 (-0.86%)
OPTN : 7.84 (-0.51%)
OptiNose (OPTN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OPTN : 7.84 (-0.51%)
BioScrip, Inc. Provides Merger Update

BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today provided an update on its proposed merger with...

BIOS : 2.31 (-0.86%)
OPTN : 7.84 (-0.51%)
Market Trends Toward New Normal in NIKE, Harley-Davidson, Knowles, Sorrento Therapeutics, OptiNose, and Columbia Sportswear -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of NIKE, Inc. (NYSE:NKE), Harley-Davidson,...

SRNE : 3.93 (+1.81%)
HOG : 36.64 (+1.75%)
COLM : 99.64 (-0.69%)
KN : 17.06 (-1.44%)
NKE : 85.75 (+0.60%)
OPTN : 7.84 (-0.51%)
Option Care ASPEN Study Shows Clinical Interventions in Home Nutrition Patients Reduce Readmissions, Save Costs

Clinical interventions provided by a nutrition support team can prevent hospital readmission in patients with short bowel syndrome (SBS) receiving home parenteral nutrition (PN), saving millions...

OPTN : 7.84 (-0.51%)
Optinose Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Operational Highlights

Company reports fourth quarter and full year 2018 net XHANCE revenue of $3.0 million and $7.1 million

OPTN : 7.84 (-0.51%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Trade OPTN with:

Business Summary

OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or ENT and allergy specialists. The company's lead product consists of XHANCE nasal polyps, XHANCE Chronic sinusitis, OPN-300, OPN- 021 and...

See More

Key Turning Points

2nd Resistance Point 8.26
1st Resistance Point 8.05
Last Price 7.84
1st Support Level 7.62
2nd Support Level 7.40

See More

52-Week High 30.00
Fibonacci 61.8% 20.70
Fibonacci 50% 17.83
Fibonacci 38.2% 14.96
Last Price 7.84
52-Week Low 5.66

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar